Context Therapeutics Q3 2026 Earnings Date & Estimates

Context Therapeutics (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.

Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is intended to recruit and activate a patient’s immune system against CLDN6-expressing solid tumors, including certain ovarian, endometrial, testicular, and other cancers. CTIM-76 is being evaluated in early-stage clinical development.

Historically, Context also developed onapristone extended release, an investigational oral therapy targeting the progesterone receptor pathway for hormone-driven cancers, including certain forms of breast and gynecologic cancer. The company has since prioritized its CLDN6-focused immuno-oncology platform and continues to advance its pipeline through clinical research and collaborations in the United States and other markets as applicable.